Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ADPT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Bacteriophage | Prosthetic Joint Infection | Phase 2 · NCT05269134 | Withdrawn |
| Bendamustine | Lymphoma | Phase 2 · NCT06557330 | Not yet recruiting |
| Anti-CD20 Monoclonal Antibody | Chronic Lymphocytic Leukemia (CLL) | Phase 2 · NCT04419519 | Active not recruiting |
| Immunotherapeutic Agent | Multiple Myeloma | N/A · NCT05271630 | Active not recruiting |
| Proteasome Inhibitor | Multiple Myeloma | N/A · NCT05271630 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not ADPT's own candidates): Glofitamab, Mosunetuzumab, Nivolumab, Obinutuzumab, Pirtobrutinib, Rituximab, Venetoclax.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ADPT holds $371.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $8M/quarter from operations, an estimated runway of 140 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADPT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 5%+ holder (13G) | 29,993,708 | 18.79% | 2026-03-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 11,992,448 | 7.51% | 2025-12-31 |
| Chad M Robins CEO and Chairman, Director |
Insider | 2,180,518 | 1.37% | 2026-08-17 |
| Harlan S Robins Chief Scientific Officer |
Insider | 812,058 | 0.51% | 2026-07-21 |
| Susan Bobulsky Chief Commercial Officer, MRD |
Insider | 395,794 | 0.25% | 2026-09-15 |
| Julie Rubinstein President and COO · +425,508 options |
Insider | 377,802 | 0.24% | 2026-04-27 |
| Kyle Piskel Chief Financial Officer |
Insider | 256,725 | 0.16% | 2026-05-18 |
| Francis Lo Chief People Officer · +272,046 options |
Insider | 223,367 | 0.14% | 2026-09-16 |
| Sharon Benzeno Chief Commercial Ofc Imm Med · +238,176 options |
Insider | 221,278 | 0.14% | 2026-06-26 |
| Peter M Neupert Director |
Insider | 130,625 | 0.08% | 2026-08-17 |
| Katey Einterz Owen Director |
Insider | 66,100 | 0.04% | 2026-08-31 |
| Robert Hershberg Director |
Insider | 46,683 | 0.03% | 2026-08-18 |
Share count 159,595,842 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADPT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →